|
Palo Alto, CA, October 21, 2003 — Telik, Inc. (Nasdaq:
TELK) announced positive interim results from its Phase 1-2a clinical
trial using escalating doses of TELCYTA™ in combination with
carboplatin in patients with platinum refractory or resistant ovarian
cancer. At the time of interim analysis, eight patients being treated
at TELCYTA™ (500 mg/m2) and carboplatin (AUC 5 or 6) are evaluable.
All patients have platinum refractory or resistant disease. Five
of the eight evaluable patients (63%) have objective tumor responses
by the RECIST criteria, including one complete response. The overall
disease stabilization rate is 88%. TELCYTA™ in combination
with carboplatin has been well-tolerated in this patient population.
The longest duration of treatment with the combination is greater
than nine months (9+ cycles). Patient enrollment and dose escalation
continues.
These data follow the previously reported single agent anti-tumor
activity of TELCYTA™ confirmed in two Phase 2 trials in ovarian
cancer, and represent an important step in the product development
process to establish potential use in less advanced cancer patients.
Telik intends to present additional results from this clinical trial
at the American Association of Cancer Research — National
Cancer Institute — European Organization for Research and
Treatment of Cancer - International Conference on Molecular Targets
and Cancer Therapeutics in November 2003.
About Telik, Inc.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™. Telik’s product candidates were discovered
using its proprietary technology, TRAP, which enables the rapid
and efficient discovery of small molecule drug candidates. Additional
information is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding our ability to
successfully develop TELCYTA™ for the treatment of any cancer,
its tolerability, potential efficacy or market potential. Telik
can give no assurance with regard to these statements. None of our
products have been determined to be safe or effective in humans
or been approved for marketing. Substantial additional testing,
including randomized, controlled clinical trials of TELCYTA™
will be necessary prior to seeking marketing approval. There can
be no assurance that such trials will accrue sufficient patients,
be conducted with sufficient quality, in a timely manner, have a
successful outcome, or that regulatory approval will be obtained.
In addition, we are reliant on external manufacturing, and any interruption
or delay in drug supply could adversely affect the development program.
More detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Telik’s
periodic filings with the Securities and Exchange Commission. Telik
assumes no obligation to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
